Peptide manufacturing is where the commercial GLP-1 era is being decided. The bottleneck shifted in 2024-2025 from API supply (where Bachem, PolyPeptide, CordenPharma, and AmbioPharm collectively expanded multiple sites) to drug product fill-finish and device assembly. Lilly's $4.5B Lebanon Advanced Therapies investment and additional LEAP District commitments, Novo Nordisk's $16.5B Catalent acquisition, and CordenPharma's $200M+ Swiss greenfield plus the $118.96M AmbioPharm Aiken County expansion are sized for the next decade of injectable peptide demand.
Drug product complexity is the new attention point. The June 19, 2026 PharmTech feature emphasized that successful peptide manufacturing in prefilled syringes for high-speed autoinjectors requires a coordinated lifecycle integrating formulation design, Cpk-driven quality control, and factory acceptance testing — increasingly relevant as GLP-1, amylin, and triagonist peptides reach commercial scale. Environmental sustainability is also moving from optional to expected: AusteinPX-led commentary frames early formulation choices as 80% of a drug's environmental impact, and solvent-free fusion-based alternatives are entering practice. PolyPeptide's Vinnova-funded green GLP-1 synthesis project with Red Glead Discovery has demonstrated that DMF-free GLP-1 manufacturing is feasible.
The regulatory layer: the EMA's first-ever synthetic peptide guideline (EMA/CHMP/CVMP/QWP/367182/2025) took effect June 1, 2026, codifying manufacturing-route and impurity expectations across human and veterinary peptide APIs. Stories here cover SPPS capacity, drug product device assembly, green chemistry, and the GLP-1 supply economy. See [[bachem]], [[polypeptide]], [[cordenpharma]], and [[manufacturing]].
Pharmaceutical Technology's June 19, 2026 Weekly Roundup centered on two peptide-manufacturing best-practices features. Ajoy Koppolu argued that successful peptide manufacturing in prefilled syringes for high-speed autoinjectors requires a coordinated lifecycle approach integrating formulation design, Cpk-driven quality control, and factory acceptance testing to ensure consistent, compliant dose delivery — increasingly the bottleneck as injectable GLP-1, amylin, and triple-agonist peptides enter commercial scale. Separately, Elizabeth Hickman (CEO of AusteinPX) argued that early formulation and manufacturing decisions drive up to 80% of a drug's environmental impact, and that solvent-free, fusion-based alternatives to traditional spray-dried dispersion offer simultaneous operational and environmental gains — relevant as PolyPeptide and EMA both pursue greener GLP-1 manufacturing pathways.
AmbioPharm announced June 16 a $118.96 million expansion of its Aiken County, South Carolina headquarters, adding a 68,000-square-foot modular manufacturing building at its existing 1024 Dittman Court campus in North Augusta and creating more than 200 new jobs. The facility will offer commercial-scale GMP synthesis including solid-phase peptide synthesis (SPPS), liquid-phase peptide synthesis (LPPS), and hybrid approaches, mirroring upgrades made to AmbioPharm's Shanghai facility. Operations target end of 2027. The announcement arrives roughly three weeks after the May 27, 2026 close of CordenPharma's acquisition of AmbioPharm, which secured CordenPharma a second US peptide site (joining Boulder, Colorado) and its first Shanghai-based supply node. AmbioPharm shareholders are reinvesting in the combined entity. The expansion is the largest single US peptide-manufacturing capacity addition of 2026 to date.
Hims & Hers reports Q1 2026 results May 11 after market close. Company guidance: $600–625M revenue (2–7% YoY) and $35–55M adjusted EBITDA (~7% margin), with Q1 carrying a roughly $65M timing impact from the weight-loss shift to 503A fulfillment. Outlook (ex-Eucalyptus) is $2.7–2.9B revenue and $300–375M EBITDA. Hims also launched Testosterone Rx+ — a once-daily pill for low-libido idiopathic hypogonadism — as a non-GLP-1 specialty addition, signaling the wider longevity and peptide play the company has telegraphed for 2026. The California peptide-manufacturing facility acquired in February 2025 sits as a post-PCAC option for producing reclassified Category 1 peptides if the July meeting clears the path.
An investor-facing April 2026 deep dive analyzes Hims & Hers' transformation from compounded GLP-1 distributor to dual-supplier branded telehealth platform after the Novo Nordisk settlement (March 9, 2026), the Eli Lilly partnership expansion (April 23), and the FDA Category 2 peptide reclassification. The piece argues the California peptide manufacturing facility acquired in 2025 — originally for compounded GLP-1s — could pivot to producing reclassified peptides like BPC-157, TB-500, and KPV if July's PCAC clears the path.